Anidulafungin: A new echinocandin for candidal infections

Pola de la Torre, Annette C. Reboli

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Anidulafungin, a new echinocandin, has recently been approved for the treatment of esophageal candidiasis, candidemia and other forms of invasive candidiasis, such as peritionitis and intra-abdominal abscesses in non-neutropenic patients. It Is fungicidal against Candida spp. including those that are azole- and polyene-resitant and fungistatic against Aspergillus spp. Owing to its poor oral bioavailability it can only be administered intravenously. Its pharmacokinetics allow for once-daily dosing and a steady state concentration is easily achieved on day 2 following a loading dose of double the maintenance dose on day 1. It does not need adjustment for hepatic or renal insufficiency; there are no known drug interactions and it has a favorable tolerability profile. Its mechanism of action, which differs from other classes of antifungals, should prevent cross-resistance with azoles and polyenes.

Original languageEnglish (US)
Pages (from-to)45-52
Number of pages8
JournalExpert Review of Anti-Infective Therapy
Issue number1
StatePublished - Feb 2007
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases
  • Virology
  • Microbiology


Dive into the research topics of 'Anidulafungin: A new echinocandin for candidal infections'. Together they form a unique fingerprint.

Cite this